Precipio Inc. (NASDAQ: PRPO) stock gained by 18.47% at last close while the PRPO stock price plunged by 4.08% in the pre-market trading session. Precipio has established a system to eliminate misdiagnostics by using intelligence, expert knowledge, and technology formed in academical institutions, and to provide physicians, their patients around the world, and proprietary software that serve laboratories throughout the world with value diagnostic information.
What is happening?
As part of its series of diagnostic tests, PRPO announced the debut of the HemeScreen Anemia Panel. This panel aims to help doctors tackle one of the clinical issues that they face: unexplained causes of anemia.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
The HemeScreen Anemia Panel from Precipio is a straightforward blood test to identify molecular genetic defects that indicate catastrophic acute leukemia. A fast and easy test, carried out in the doctor’s office, leads the physician to do additional suitable testing and treatment of the hematological.
As per the WHO, over 24 percent or 1,62 billion people worldwide are affected by anemia, and over a million individuals in the US have anemia yearly according to the American Society of Hematology.
While there are other variables which might cause these deficits, the definition of anemia is a lack in the quantity or volume of red blood cells, or in the concentration of hemoglobin. Such variables might include iron shortage, hemorrhage, hereditary diseases, shortages in nutrients, etc.
Furthermore,
The molecular testing to find genetic abnormalities in the bone marrow or cells in the blood is one means of deciding if anemia is related with malignancies. However, few approaches for evaluating anemia-related patients are accessible. The tests now on the market are either too simplistic or for instance, a complete blood count (CBC), which evaluates numerous components within the blood but doesn’t give an insight into the patient’s genetics; or it is too slow and costly, such as next-generation sequencer (NGS).